Genome editing in the mouse brain with minimally immunogenic #Cas9 RNPs Cell penetrant Cas9 RNPs demonstrated effective editing in the mouse striatum, reducing immune responses. Transient delivery of immunogenic #CRISPR RNPs shows promise for precise genome editing.

Heterologous COVID-19 vaccine schedules in adolescents using NVXCoV2373 after BNT162b2 may offer enhanced protection. #COVID19

Imagine if you could rapidly detect COVID-19 in public places by testing the air. Now you can! Researchers have developed a groundbreaking new air monitor that can detect the presence of an infected person in as little as 5 minutes. 🧵 nature.com/articles/s4146…

We identified novel antivirals targeting SARS-COV-2, characterized them, and got high-resolution images of 1 bound to Spike. Collaboration with groups from IQM_CSIC I2SysBio and IBV-CSIC. Funding from saludglobalCSIC @GVAinnova and CRUE-SANTANDER. doi.org/10.1021/acs.jm…

The paradigm of developing a novel technology and applying it to a clinically relevant problem may be dominant in academic medicine, but more emphasis is needed in identifying important clinical problems before looking for solutions go.nature.com/3QgruSZ rdcu.be/dicHm

My attempt at a COMPLETE LIST of all of the diseases/programs and cancer treatments that are in development by #CRISPR #GeneEditing companies All in IND-enabling studies or clinic... 1. Sickle Cell Disease (CRSP, EDIT, BEAM) 2. Beta Thalassemia (CRSP, EDIT, BEAM) 3. ATTR-

Several people asked me for highlights of the #longcovid Keystone conference #KSLongCoVID24. I’ll mention a few, personal, highlights. 1/x

Super-precise #CRISPR tool enters US clinical trials for the first time nature.com/articles/d4158…

Drug delivery systems for #CRISPR-based genome editors nature.com/articles/s4157…

🧬 New-gen genome editors with potentially higher fidelity and capable of longer edits are here! Think prime editing but with DNA-dependent DNA polymerases instead of a RT. A comparison of recent tools from ErikSontheimerLab & Ben Kleinstiver Lab. Thread 🧵:

Gene therapies for rare diseases are under threat. Scientists hope to save them. go.nature.com/3Q4BnCr

Should you go preferentially for a Novavax booster? The limited data that we have and what I wound up doing this week Science Magazine by J Couzin-Frankel science.org/content/articl…

For readers interested in drug delivery systems for CRISPR-based genome editors such as AAVs and lipid nanoparticles, here's a comprehensive recent review bit.ly/3tTMzZY

EMA-Workshop on generating evidence for #LongCovid and #PASC treatment LCE will attend the panel discussion at the upcoming EU Medicines Agency workshop on 17.11.2023, along representatives from industry, academia and policy U.S. FDA. Info & link for live broadcast: ema.europa.eu/en/events/work…

Equitable healthcare and personalized medicine for every person, regardless of their genetic makeup, is both commendable and essential. Great to be part of this project. @scheerenlab #FAST

Today we report in Nature Medicine the development of a base editing strategy for prion disease, currently a fatal and rapidly progressing neurogenerative condition with no effective treatment. @PrionAlliance DevermanLab (1/13) drive.google.com/file/d/1DVpKrz…

As new cell and gene therapies emerge from academia, we must RISE to the opportunity go.nature.com/3Cj0T2O

Platform-based approaches for gene-editing therapies could markedly improve development efficiency, reduce costs and increase access for patients with rare diseases go.nature.com/4kCD1Y3 rdcu.be/ezpF3

Excited to share our new protocol in #NatureProtocols! 🧬👨‍💻🎉 A comprehensive guide for using PRIDICT2.0 and ePRIDICT machine learning tools to design efficient #CRISPR-Cas9 prime editing experiments. 🧵 UZH Science Gerald Schwank Krauthammer Lab nature.com/articles/s4159…